Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
about
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavirClinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy.Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir.
P2860
Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy.
description
1997 nî lūn-bûn
@nan
1997 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Exposure-response relationship ...... tabine in combination therapy.
@ast
Exposure-response relationship ...... tabine in combination therapy.
@en
type
label
Exposure-response relationship ...... tabine in combination therapy.
@ast
Exposure-response relationship ...... tabine in combination therapy.
@en
prefLabel
Exposure-response relationship ...... tabine in combination therapy.
@ast
Exposure-response relationship ...... tabine in combination therapy.
@en
P2093
P2860
P1476
Exposure-response relationship ...... tabine in combination therapy.
@en
P2093
A C Collier
G F Vanhove
L B Sheiner
T F Blaschke
P2860
P304
P407
P577
1997-11-01T00:00:00Z